Predicted Biological Activity of Intravitreal VEGF TRAP

¹ Mayo Clinic Jacksonville, United States
² Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, United States

^* To whom correspondence should be addressed. E-mail: stewart.michael{at}mayo.edu.

Accepted 11 February 2008

	Abstract

Aims: To compare the intravitreal binding activity of the VEGF TRAP with that of ranibizumab against VEGF (vascular endothelial growth factor) using a time and dose-dependant mathematical model

Methods: Intravitreal half-lives and relative equimolar VEGF binding activities of the VEGF TRAP and ranibizumab were incorporated into a first-order decay model. Time-dependant VEGF TRAP activities (relative to ranibizumab) for different initial doses (0.5 mg, 1.15 mg, 2 mg, 4 mg) were calculated and graphed

Results: Seventy-nine days following a single VEGF TRAP (1.15 mg) injection, the intravitreal VEGF binding activity would be comparable to ranibizumab at 30 days. Following VEGF TRAP injections of 0.5 mg, 2 mg and 4 mg, the intravitreal VEGF binding activities (comparable to ranibizumab at 30 days) would occur at 73 days, 83 days and 87 days respectively

Conclusion: Based upon this mathematical model, the VEGF TRAP maintains a significant intravitreal VEGF binding activity for 10 to 12 weeks following a single injection.